Wegovy vs Ozempic in Australia: Key Differences
A plain overview of how Wegovy and Ozempic, both semaglutide, differ by registered indication, dose range and PBS status in Australia. General information only, not legal or medical advice.
The short answer
Wegovy and Ozempic are both brand names for the same active ingredient, semaglutide, made by Novo Nordisk. The main difference is what each product is registered for in Australia. Ozempic is registered for the treatment of type 2 diabetes in adults, while Wegovy is registered for chronic weight management. They differ in their approved strength and dose range, in some device details, and in their Pharmaceutical Benefits Scheme, or PBS, status.
Both are prescription-only medicines in Australia. They are supplied through pharmacies on a doctor's prescription and are not sold by general retailers. NovaPeptides does not sell Wegovy, Ozempic or semaglutide, and this article does not recommend either product or make any claim about results.
This is general information only and not legal or medical advice. Regulatory status can change. Always check the TGA and PBS for the current position and speak to a qualified health professional about any medicine.
Same molecule, two brands
Semaglutide is a GLP-1 receptor agonist. Novo Nordisk markets it under more than one brand name. In Australia the two injectable brands most often compared are Ozempic and Wegovy. Because the active ingredient is the same, people frequently assume the two products are interchangeable. From a regulatory point of view they are not, because each brand is registered for a different purpose and comes in a different dose range.
When a medicine is entered on the Australian Register of Therapeutic Goods, or ARTG, it is registered for specific approved uses known as indications. The indication, the approved strengths and the product information are all tied to the individual brand, not simply to the molecule. That is why Ozempic and Wegovy, despite sharing semaglutide, are treated as separate registered products.
Shared features
- Active ingredient: semaglutide
- Manufacturer: Novo Nordisk
- Drug class: GLP-1 receptor agonist
- Administration: once weekly subcutaneous injection via a pre-filled pen
- Status in Australia: prescription-only medicine
What Ozempic is registered for
In Australia, Ozempic is registered with the TGA for the treatment of type 2 diabetes in adults. It is used to improve blood glucose control and, in its approved product information, has associated cardiovascular considerations in people with type 2 diabetes. It is not registered in Australia as a weight loss medicine, even though semaglutide is the same molecule found in Wegovy.
Ozempic is supplied in a pre-filled pen and, as at the time of writing, is available in strengths commonly described as 0.25 mg, 0.5 mg, 1 mg and 2 mg per weekly dose, with lower starting strengths used before higher ones. The exact strengths and pen configurations should always be confirmed against the current TGA product information, because product ranges can change over time.
What Wegovy is registered for
Wegovy is registered with the TGA for chronic weight management. Its approved indication relates to adults who meet certain body mass index criteria, with additional criteria published in its product information, and it also carries an approved use connected to cardiovascular risk reduction in defined groups. Because registered indications and eligibility criteria are detailed and can be updated, the current TGA product information is the authoritative source.
Wegovy reaches a higher maintenance strength than Ozempic. It is commonly described as building up to a 2.4 mg weekly dose. The dosing ladder and pen presentation differ from Ozempic, which is one of the practical reasons the two brands are not treated as simple substitutes even though the molecule is identical.
This article does not provide dosing instructions or a protocol for any medicine. Strengths are mentioned only as registered product facts. Any use of a prescription medicine must be directed by a qualified prescriber.
PBS status and cost
The Pharmaceutical Benefits Scheme subsidises the cost of many medicines in Australia. Ozempic has had a PBS listing for type 2 diabetes, subject to the scheme's eligibility criteria. This means some people prescribed Ozempic for its registered diabetes indication may access it at a subsidised price when they meet those criteria.
Wegovy, as at the time of writing, is registered with the TGA but is generally supplied on a private prescription rather than being subsidised on the PBS for chronic weight management. A PBS listing for semaglutide 2.4 mg has been the subject of Pharmaceutical Benefits Advisory Committee consideration, but listings and their criteria can change. Because PBS arrangements are updated regularly, the current PBS Schedule is the only reliable place to confirm whether either product is subsidised and under what conditions.
Supply context and off-label use
Australia has experienced well documented supply pressure on semaglutide products, with Ozempic in particular subject to shortages that the TGA has publicly tracked and managed through supply updates. Supply status changes over time, so the TGA medicine shortage reports are the appropriate place to check the current position for each brand.
There has also been public discussion of off-label prescribing, where a medicine registered for one indication is prescribed for a different purpose at a prescriber's discretion. The TGA has commented on this topic in the context of semaglutide. This article does not encourage or advise off-label use. Decisions about any prescription medicine, including whether a particular brand or indication is appropriate, are matters for a qualified health professional.
Registered indications, supply status and subsidy arrangements can all change. Treat any single snapshot as a starting point and verify against the TGA and PBS.
Where NovaPeptides fits
It is worth being clear about categories. Wegovy and Ozempic are approved prescription medicines, registered on the ARTG and supplied through pharmacies on a doctor's prescription. NovaPeptides is not a pharmacy and does not sell, supply or import Wegovy, Ozempic or semaglutide, and nothing here should be read as an offer to do so.
NovaPeptides supplies research-grade compounds intended for laboratory research use only. That is a different category from an approved, prescription-only therapeutic good. A research-use-only compound is not a medicine, is not for human or veterinary use, and is not a substitute for a product that a doctor may prescribe. If you are looking at Wegovy or Ozempic for a health reason, the appropriate path is a conversation with a qualified prescriber, not a research supplier.
Approved prescription medicine and research-use-only compound are not the same thing. This article compares two registered medicines for information only and makes no recommendation about either.
How to check current facts
Where to confirm the current position
- ARTG registration and product information: the TGA website and the ARTG search
- PBS subsidy status and eligibility criteria: the current PBS Schedule
- Medicine shortages and supply updates: the TGA medicine shortage reports
- Indications, strengths and device details: the approved product information for each specific brand
- Personal suitability: a qualified doctor or pharmacist
Because the regulatory landscape for semaglutide in Australia continues to evolve, any date, approval or subsidy mentioned in general writing should be treated as a pointer rather than the final word. The official sources above hold the current and authoritative detail.
Frequently asked questions
Are Wegovy and Ozempic the same drug?+
They share the same active ingredient, semaglutide, made by Novo Nordisk, so chemically the molecule is the same. However they are registered as separate brands in Australia with different approved indications and different dose ranges, so they are not simply interchangeable from a regulatory standpoint.
What is each one registered for in Australia?+
As at the time of writing, Ozempic is registered with the TGA for the treatment of type 2 diabetes in adults, while Wegovy is registered for chronic weight management, with criteria set out in its product information. Always confirm current indications against the TGA.
Is Wegovy on the PBS?+
As at the time of writing, Wegovy is TGA registered but is generally supplied on a private prescription rather than being PBS subsidised for chronic weight management. PBS consideration has occurred and arrangements can change, so check the current PBS Schedule for the latest position.
Is Ozempic subsidised?+
Ozempic has had a PBS listing for type 2 diabetes subject to the scheme's eligibility criteria. Whether an individual qualifies depends on those criteria, so the current PBS Schedule and a prescriber are the right sources to confirm.
Can I buy Wegovy or Ozempic from NovaPeptides?+
No. Both are prescription-only medicines supplied through pharmacies on a doctor's prescription. NovaPeptides is not a pharmacy and does not sell Wegovy, Ozempic or semaglutide. NovaPeptides supplies research-grade compounds for laboratory research use only.
Why has there been an Ozempic shortage in Australia?+
Australia has had well documented supply pressure on semaglutide products, including Ozempic, which the TGA has tracked through its medicine shortage reports. Supply status changes over time, so the TGA shortage reports hold the current picture for each brand.
Which one is better?+
This article does not recommend one over the other or make any claim about outcomes. They are registered for different purposes, so the appropriate comparison depends entirely on an individual's situation, which is a matter for a qualified health professional.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp